Michael Raab, President and Chief Executive Officer of Ardelyx, Inc. (NASDAQ: ARDX), completed the sale of 41,666 shares of the company's common stock on March 16, 2026, according to a Form 4 filing. The trades were executed in several transactions at per-share prices ranging from $5.79 to $5.92, producing proceeds of approximately $243,329.
In the same filing, the CEO disclosed the exercise of stock options to purchase 20,833 shares of Ardelyx common stock at an exercise price of $0.99 per share. The reported aggregate cost for that option exercise was $20,624.
After accounting for the sales and the option exercise, Raab is reported to directly own 1,816,448 shares of Ardelyx common stock. That direct total includes 1,128 shares acquired through the company's employee stock purchase plan on February 27, 2026. The filing also indicates indirect holdings of 24,364 shares through a family trust and 1,000 shares held in trusts established for the benefit of his children.
The transactions were conducted pursuant to a 10b5-1 trading plan the reporting person adopted on November 7, 2025. The Form 4 notes that the option exercised becomes exercisable as it vests, with the shares subject to the option vesting in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, conditioned on the reporting person's continued employment or service relationship with the issuer on each applicable vesting date.
Market context in the filing shows Ardelyx shares trading at $5.56 at the time of reporting, a level below a referenced fair value assessment of $6.80. The filing and related disclosures underscore a continued equity stake by the CEO while documenting a routine liquidity event executed under a pre-established trading plan.
Beyond insider activity, Ardelyx has communicated several corporate developments. The company pre-released fourth-quarter 2025 revenue figures for its products Ibsrela and Xphozah and provided fiscal 2026 product revenue guidance, forecasting Ibsrela revenue in a range of $410 million to $430 million and Xphozah revenue between $110 million and $120 million.
Ardelyx also announced the initiation of the ACCEL Phase 3 clinical trial for IBSRELA, a study intended to assess the efficacy and safety of the treatment for chronic idiopathic constipation in adults. Separately, the U.S. Patent and Trademark Office issued a patent for tenapanor that could extend exclusivity for the compound to 2042, a development noted in subsequent analyst commentary.
Analysts responded to the patent news and other company updates with bullish assessments and price target adjustments. H.C. Wainwright raised its target to $18.00 while maintaining a Buy rating. Raymond James reiterated a Strong Buy rating with a $19.00 price target. Leerink Partners reiterated an Outperform rating and a $17.00 price target, and Piper Sandler maintained an Overweight rating, citing Ibsrela's growth trajectory.
Those analyst positions reflect external confidence in Ardelyx's commercialization strategy and pipeline execution, while the insider transaction documents show Raab balancing personal liquidity and ongoing ownership. The Form 4 disclosures, the company's revenue guidance and the patent issuance together paint a picture of a company at the intersection of commercial scaling and intellectual property extension.
While the Form 4 provides specific, dated details of the transactions and ownership positions, it does not alter the factual record about the company's forward guidance and trial commencement. Investors and observers should note that the sales were made under a prearranged trading plan and that the option exercise is subject to vesting terms tied to continued service.